Aspira Women's Health Faces Delisting Notice

Ticker: AWHL · Form: 8-K · Filed: Dec 31, 2024 · CIK: 926617

Sentiment: bearish

Topics: delisting, listing-rule-violation, company-update

TL;DR

Aspira Women's Health (AWH) got a delisting warning, might be in trouble.

AI Summary

Aspira Women's Health Inc. filed an 8-K on December 31, 2024, to report a notice of delisting or failure to satisfy a continued listing rule. The company was formerly known as Vermillion, Inc., Ciphergen Biosystems Inc., and Abiotic Systems.

Why It Matters

This filing indicates potential issues with Aspira Women's Health's continued listing on an exchange, which could impact its stock trading and investor confidence.

Risk Assessment

Risk Level: high — A notice of delisting directly threatens the company's ability to remain publicly traded, posing a significant risk to investors.

Key Players & Entities

FAQ

What specific listing rule did Aspira Women's Health Inc. fail to satisfy?

The filing does not specify the exact listing rule that was not satisfied, only that a notice of delisting or failure to satisfy a continued listing rule was issued.

When was the notice of delisting or failure to satisfy a continued listing rule issued?

The earliest event reported in this 8-K filing is dated December 31, 2024, which is when the notice was likely issued or became effective.

What are the previous names of Aspira Women's Health Inc.?

Aspira Women's Health Inc. was formerly known as Vermillion, Inc., Ciphergen Biosystems Inc., and Abiotic Systems.

What is the business address of Aspira Women's Health Inc.?

The business address is 12117 Bee Caves Road, Building Three, Suite 100, Austin, TX 78738.

What is the SIC code for Aspira Women's Health Inc.?

The Standard Industrial Classification (SIC) code for Aspira Women's Health Inc. is 2835, which corresponds to 'IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES'.

Filing Stats: 637 words · 3 min read · ~2 pages · Grade level 14.3 · Accepted 2024-12-31 17:21:41

Key Financial Figures

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Aspira Women's Health Inc. Date: December 31, 2024 By: /s/ Sandra Milligan Sandra Milligan, Interim Chief Executive Officer -3-

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing